The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings

摘要: Rituximab has improved the prognosis of patients with diffuse large B-cell lymphoma, but a high proportion advanced disease will relapse or fail to achieve remission front-line treatment. Salvage chemotherapy, followed by high-dose chemotherapy radiation therapy and autologous stem cell transplantation, remains best treatment option for such patients, especially those who retain chemosensitivity. Allogeneic transplantation is under investigation in this setting, often as after transplantation. Treatment-related mortality due graft-versus-host disease, preparative regimen toxicity, poor immune recovery limits its benefits. This article reviews role hematopoietic incorporation rituximab, avenues clinical rapidly evolving field.